Purine derivatives for the treatment of viral infections

1. A compound of formula (I)

or a pharmaceutically acceptable salt, solvate or polymorph thereof, wherein Y is C 1-4 alkylene,

R 1 is selected from the group consisting of imidazolyl, pyrimidyl, pyrrolyl, pyrazolyl, furyl, oxazolyl, oxadiazolyl, isoxazolyl, pyrazinyl and thiazolyl, wherein R 1 is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, C 1-6 alkyl, C 1-4 alkoxy, trifluoromethyl, C 3-6 cycloalkyl, phenyl, halogen, hydroxyl-C 1-4 alkyl, C 1-4 -alkoxy-C 1-4 -alkyl- and C 1-4 alkyl-diethoxyphosphoryl R 2 is selected from a group consisting of phenyl, naphtyl, anthracenyl and phenanthrenyl, wherein R 2 is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, C 1-6 alkyl, C 1-4 alkoxy, trifluoromethyl, CO 2 R 3 , halogen, hydroxyl-C 1-4 alkyl-, NR 6 R 7 , C(O)R 6 , C(O)NR 6 R 7 , C 1-4 alkyl-diethoxyphosphoryl or C 1-4 alkyl-phosphonic acid;

R 3 is selected from H and C 1-6 alkyl;

R 6 and R 7 are each independently selected from H, C 1-6 alkyl or C 1-4 alkoxy—after C 1-4 alkyl-diethoxyphosphoryl.

2. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 , together with one or more pharmaceutically acceptable excipients, diluents or carriers.

3. A compound selected from the group consisting of:

4. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 3 , together with one or more pharmaceutically acceptable excipients, diluents or carriers.